^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Yondelis (trabectedin)

    i
    Company:
    J&J, Otsuka, PharmaMar, Specialised Therap, Valeo Pharma
    Drug class:
    Alkylating agent, DNA inhibitor
    Related drugs:
    Apply
    SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma (NCT03138161)
    Phase 1/2
    Sarcoma Oncology Research Center, LLC
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    04/13/2017
    Primary completion :
    12/31/2030
    Completion :
    07/31/2031
    PD-L1 • PD-1
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Yondelis (trabectedin)
    Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments. (TOMAS2) (NCT03838744)
    Phase 2
    Italian Sarcoma Group
    Completed
    Last update posted :
    12/04/2024
    Initiation :
    05/20/2020
    Primary completion :
    11/29/2024
    Completion :
    11/29/2024
    BRCA1 • BRCA2 • BRCA
    |
    Lynparza (olaparib) • Yondelis (trabectedin)
    tTF-NGR Randomized Study - STS (TRABTRAP) (NCT05597917)
    Phase 3
    Universität Münster
    Recruiting
    Last update posted :
    12/22/2023
    Initiation :
    10/26/2021
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    BCOR • ANPEP
    |
    Yondelis (trabectedin)
    SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients (NCT04067115)
    Phase 1/2
    Sarcoma Alliance for Research through Collabora...
    Active, not recruiting
    Last update posted :
    12/21/2023
    Initiation :
    01/05/2021
    Primary completion :
    06/30/2024
    Completion :
    06/30/2024
    EWSR1 • FLI1
    |
    irinotecan • Yondelis (trabectedin)
    Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma (ISG-MCS) (NCT04305548)
    Phase 2
    Italian Sarcoma Group
    Recruiting
    Last update posted :
    09/13/2023
    Initiation :
    09/14/2021
    Primary completion :
    09/01/2024
    Completion :
    12/31/2024
    HEY1 • NCOA2
    |
    Yondelis (trabectedin)
    Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (TRASTS) (NCT02275286)
    Phase 1/2
    Grupo Espanol de Investigacion en Sarcomas
    Recruiting
    Last update posted :
    05/31/2023
    Initiation :
    11/01/2014
    Primary completion :
    06/01/2028
    Completion :
    06/01/2028
    FAS
    |
    Yondelis (trabectedin)
    Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas. (TRAMUNE) (NCT03085225)
    Phase 1
    Institut Bergonié
    Completed
    Last update posted :
    03/03/2023
    Initiation :
    05/05/2017
    Primary completion :
    11/19/2020
    Completion :
    01/04/2022
    BRCA
    |
    BRCA mutation
    |
    Imfinzi (durvalumab) • Yondelis (trabectedin)
    Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas (NiTraSarc) (NCT03590210)
    Phase 2
    University Medicine Greifswald
    Completed
    Last update posted :
    11/08/2022
    Initiation :
    06/08/2018
    Primary completion :
    02/12/2022
    Completion :
    02/12/2022
    PD-L1 • CTLA4
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yondelis (trabectedin)
    Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma (NCT03470805)
    Phase 2
    Grupo Español de Investigación en Cáncer de Ovario
    Completed
    Last update posted :
    09/23/2022
    Initiation :
    06/21/2018
    Primary completion :
    07/27/2022
    Completion :
    07/27/2022
    BRCA1 • BRCA2 • BRCA
    |
    Lynparza (olaparib) • pegylated liposomal doxorubicin • Yondelis (trabectedin) • doxorubicin liposomal
    Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum (TvsCH) (NCT05512676)
    Phase N/A
    Oslo University Hospital
    Completed
    Last update posted :
    08/23/2022
    Initiation :
    03/07/2016
    Primary completion :
    05/20/2019
    Completion :
    08/01/2022
    BRCA
    |
    cisplatin • carboplatin • pegylated liposomal doxorubicin • Yondelis (trabectedin)
    Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients (NIMES-ROC) (NCT02825420)
    Phase N/A
    PharmaMar
    Completed
    Last update posted :
    10/29/2021
    Initiation :
    07/28/2015
    Primary completion :
    09/18/2019
    Completion :
    09/18/2019
    BRCA1 • BRCA2
    |
    Yondelis (trabectedin)
    Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients (Mito23) (NCT02903004)
    Phase 3
    Fondazione Policlinico Universitario Agostino G...
    Completed
    Last update posted :
    08/25/2021
    Initiation :
    04/11/2016
    Primary completion :
    12/20/2018
    Completion :
    12/20/2018
    BRCA • MUC16
    |
    BRCA mutation
    |
    carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Yondelis (trabectedin) • topotecan • doxorubicin liposomal
    Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS) (NCT02398058)
    Phase 1
    Italian Sarcoma Group
    Completed
    Last update posted :
    04/14/2021
    Initiation :
    07/20/2014
    Primary completion :
    12/01/2019
    Completion :
    12/01/2019
    BRCA1 • ERCC1 • ERCC2 • PARP1 • TP53BP1
    |
    Lynparza (olaparib) • Yondelis (trabectedin)
    ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM) (NCT02194231)
    Phase 2
    Mario Negri Institute for Pharmacological Research
    Completed
    Last update posted :
    01/23/2020
    Initiation :
    07/01/2013
    Primary completion :
    12/12/2019
    Completion :
    12/12/2019
    HMGB1
    |
    Yondelis (trabectedin) • dexamethasone injection
    Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma (NCT03397186)
    Phase 2
    Fred Hutchinson Cancer Center
    Withdrawn
    Last update posted :
    09/10/2019
    Initiation :
    06/19/2018
    Primary completion :
    01/01/2021
    Completion :
    05/01/2021
    CD8 • LAG3 • CTLA4 • CD4 • CCR5 • CXCR3
    |
    CCR5 expression
    |
    Yondelis (trabectedin)
    A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT01846611)
    Phase 3
    Janssen Research & Development, LLC
    Completed
    Last update posted :
    04/01/2019
    Initiation :
    10/16/2013
    Primary completion :
    01/18/2018
    Completion :
    11/16/2018
    BRCA1 • BRCA2 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    pegylated liposomal doxorubicin • Yondelis (trabectedin) • dexamethasone • dexamethasone injection • doxorubicin liposomal